Phototherapy and photochemotherapy for polymorphic light eruption desensitisation: a five year case series review from a university teaching hospital

A. Aslam; L. Fullerton; S. H. Ibbotson

doi:10.1111/phpp.12310

Phototherapy and photochemotherapy for polymorphic light eruption desensitisation: a five year case series review from a university teaching hospital

A. Aslam, L. Fullerton, S. H. Ibbotson (Lead / Corresponding author)

Undergraduate Medicine

Research output: Contribution to journal › Letter › peer-review

9 Citations (Scopus)

376 Downloads (Pure)

Abstract

Polymorphic light eruption (PLE) is the most common immunological photodermatosis, with a prevalence of 18% in Europe1. The pathogenesis of PLE appears to involve delayed cell mediated hypersensitivity and aberrant Langerhans cell function2,3. Phototherapy, using narrowband UVB (UVB) or psoralen-ultraviolet A (PUVA) photochemotherapy, is widely used for prophylactic desensitisation in PLE, with benefit experienced in 90% of patients4,5

Original language	English
Pages (from-to)	225-227
Number of pages	3
Journal	Photodermatology, Photoimmunology & Photomedicine
Volume	33
Issue number	4
Early online date	17 Apr 2017
DOIs	https://doi.org/10.1111/phpp.12310
Publication status	Published - 11 May 2017

Keywords

Phototherapy
Polymorphic light eruption
Desensitisation
UVB

Access to Document

10.1111/phpp.12310

PLE_PPP_FINAL_REVISED_04.04.17Accepted author manuscript, 440 KB

Cite this

@article{1eaf519fa5364b05890e0601e0f30084,

title = "Phototherapy and photochemotherapy for polymorphic light eruption desensitisation: a five year case series review from a university teaching hospital",

abstract = "Polymorphic light eruption (PLE) is the most common immunological photodermatosis, with a prevalence of 18% in Europe1. The pathogenesis of PLE appears to involve delayed cell mediated hypersensitivity and aberrant Langerhans cell function2,3. Phototherapy, using narrowband UVB (UVB) or psoralen-ultraviolet A (PUVA) photochemotherapy, is widely used for prophylactic desensitisation in PLE, with benefit experienced in 90% of patients4,5",

keywords = "Phototherapy, Polymorphic light eruption, Desensitisation, UVB",

author = "A. Aslam and L. Fullerton and Ibbotson, {S. H.}",

note = "no funding info",

year = "2017",

month = may,

day = "11",

doi = "10.1111/phpp.12310",

language = "English",

volume = "33",

pages = "225--227",

journal = "Photodermatology, Photoimmunology & Photomedicine",

issn = "0905-4383",

publisher = "Blackwell Munksgaard",

number = "4",

}

Phototherapy and photochemotherapy for polymorphic light eruption desensitisation: a five year case series review from a university teaching hospital. / Aslam, A.; Fullerton, L.; Ibbotson, S. H. (Lead / Corresponding author).
In: Photodermatology, Photoimmunology & Photomedicine, Vol. 33, No. 4, 11.05.2017, p. 225-227.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Phototherapy and photochemotherapy for polymorphic light eruption desensitisation

T2 - a five year case series review from a university teaching hospital

AU - Aslam, A.

AU - Fullerton, L.

AU - Ibbotson, S. H.

N1 - no funding info

PY - 2017/5/11

Y1 - 2017/5/11

N2 - Polymorphic light eruption (PLE) is the most common immunological photodermatosis, with a prevalence of 18% in Europe1. The pathogenesis of PLE appears to involve delayed cell mediated hypersensitivity and aberrant Langerhans cell function2,3. Phototherapy, using narrowband UVB (UVB) or psoralen-ultraviolet A (PUVA) photochemotherapy, is widely used for prophylactic desensitisation in PLE, with benefit experienced in 90% of patients4,5

AB - Polymorphic light eruption (PLE) is the most common immunological photodermatosis, with a prevalence of 18% in Europe1. The pathogenesis of PLE appears to involve delayed cell mediated hypersensitivity and aberrant Langerhans cell function2,3. Phototherapy, using narrowband UVB (UVB) or psoralen-ultraviolet A (PUVA) photochemotherapy, is widely used for prophylactic desensitisation in PLE, with benefit experienced in 90% of patients4,5

KW - Phototherapy

KW - Polymorphic light eruption

KW - Desensitisation

KW - UVB

U2 - 10.1111/phpp.12310

DO - 10.1111/phpp.12310

M3 - Letter

C2 - 28419574

SN - 0905-4383

VL - 33

SP - 225

EP - 227

JO - Photodermatology, Photoimmunology & Photomedicine

JF - Photodermatology, Photoimmunology & Photomedicine

IS - 4

ER -

Phototherapy and photochemotherapy for polymorphic light eruption desensitisation: a five year case series review from a university teaching hospital

Abstract

Keywords

Access to Document

Fingerprint

Cite this